Analyst Ranking
Bottom 7%
#4142 out of 4426 analysts
Average Return
Win Rate
30%13 out of 44
Risk vs Reward

Sumant Kulkarni's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Sage Therapeutics IncSAGE
2020-04-08 -
Strong Buy
Biohaven Pharmaceutical Holding Co LtdBHVN1
2018-03-27 -
Strong Buy
Alder Biopharmaceuticals IncALDR
2019-03-14 -
Strong Buy
Cybin IncCYBN
2023-09-01 -
Strong Buy
Biogen IncBIIB
2022-02-07 -
Strong Buy

Sumant Kulkarni's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neurocrine Biosciences IncNBIX
6Strong Buy$150.00+27.90%Reiterates
4 days ago
Zevra Therapeutics IncZVRA
3Strong Buy$20.00+293.70%Reiterates
3 months ago
Cybin IncCYBN
3Strong Buy$5.00+1,107.73%Reiterates
3 months ago
Compass Pathways PLCCMPS
1Strong Buy$50.00+672.80%Maintains
4 months ago
Zynerba Pharmaceuticals IncZYNE
4 months ago
Bioxcel Therapeutics IncBTAI
3Strong Buy$20.00+530.91%Maintains
4 months ago
Sage Therapeutics IncSAGE
4 months ago
Acadia Pharmaceuticals IncACAD
4Strong Buy$38.00+81.12%Maintains
4 months ago
Biogen IncBIIB
9Strong Buy$350.00+46.27%Maintains
6 months ago
Voyager Therapeutics IncVYGR
2Strong Buy$14.00+80.41%Maintains
7 months ago
Stoke Therapeutics IncSTOK
1Strong Buy$24.00+403.14%Assumes
7 months ago
Intra Cellular Therapies IncITCI
1Strong Buy$98.00+62.55%Maintains
8 months ago
Cara Therapeutics IncCARA
2Strong Buy$25.00+1,900.00%Maintains
9 months ago
Clene IncCLNN
2Strong Buy$6.00N/AMaintains
a year ago
Gh Research PLCGHRS
2Strong Buy$41.00N/AMaintains
2 years ago
Quince Therapeutics IncQNCX
2 years ago
Biohaven Pharmaceutical Holding Co LtdBHVN1
3Strong Buy$150.00N/AMaintains
2 years ago
Alder Biopharmaceuticals IncALDR
2Strong Buy$20.00N/AMaintains
5 years ago
Avexis IncAVXS
6 years ago
Teva Pharmaceutical Industries LtdTEVA
1Strong BuyN/AN/AUpgrades
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.